Cagrilintide is a synthetic research peptide studied as a long-acting amylin receptor agonist — a mechanism distinct from the GLP-1, GIP, and glucagon receptor pathways targeted by compounds like semaglutide, tirzepatide, and retatrutide. Developed originally by Novo Nordisk, cagrilintide has drawn significant research interest both as a standalone amylin analog and as the amylin component of CagriSema, a fixed-dose combination studied alongside semaglutide in the REDEFINE clinical trial program. Helix Bio supplies Cagrilintide as a lyophilized powder intended strictly for laboratory and preclinical research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application.
HPLC certified
Independent analysis
Highest standard
Full traceability
Cagrilintide is studied as an acylated analog of amylin, a hormone co-secreted with insulin that plays a role in satiety and gastric emptying. Unlike the GLP-1-class peptides that dominate current metabolic research, cagrilintide works through amylin receptor pathways in the brainstem rather than the GLP-1 receptor. That different mechanism is exactly why researchers study it both on its own and in combination with GLP-1 agonists like semaglutide — the two pathways are investigated for complementary rather than overlapping effects.
Helix Bio's Cagrilintide is supplied as a lyophilized (freeze-dried) powder — a synthetic peptide manufactured under controlled laboratory conditions. Lyophilization extends shelf stability prior to reconstitution, which is useful for labs running studies over an extended timeline rather than using a full vial at once.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying amylin receptor pharmacology, appetite-regulation signaling, or comparative metabolic research models.
Amylin-pathway research is a smaller, more specialized corner of metabolic science than GLP-1 research, which makes sourcing quality material even more important — there's less published literature to cross-check a bad batch against. Helix Bio manufactures its Cagrilintide domestically, backs every batch with purity testing, and issues documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for an amylin receptor agonist to study alongside or against a GLP-1 compound, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
